CARDIOVASCULAR MEDICINE

The economic burden of coronary heart disease in the UK

J L Y Liu¹, N Maniadakis¹, A Gray¹, M Rayner²

¹ Health Economics Research Centre, Institute of Health Sciences, University of Oxford, Oxford, UK
² British Heart Foundation Health Promotion Research Group, Institute of Health Sciences, University of Oxford

Correspondence to:
Correspondence to:
Dr Joseph L Y Liu, Wolfson College, Oxford OX2 6UD, UK;
joe.liu{at}public-health.ox.ac.uk

Objective: To estimate the economic burden of coronary heart disease in the UK using both direct and indirect costs.

Design and setting: A prevalence based approach was used to assess coronary heart disease related costs from the societal perspective.

Patients: All UK residents in 1999 with coronary heart disease (ICD 9 codes 410–414 and ICD10 codes I20–I25).

Main outcome measures: Direct health care costs were estimated from spending on prevention, accident and emergency care, hospital care, rehabilitation, and drug treatment. Direct non-health service costs were estimated from data on informal care. "Friction period" adjusted productivity costs were estimated using the human capital approach from lost earnings attributable to coronary heart disease related mortality and morbidity. The friction period is the period of employees’ absence from work before the employer replaces them with other workers. Failure to adjust for this factor would overstate production loss.

Results: Coronary heart disease cost £1.73 billion to the UK health care system in 1999: £2.42 billion in informal care and £2.91 billion in friction period adjusted productivity loss; 24.1% of production losses were attributable to mortality and 75.9% to morbidity. The total annual cost of all coronary heart disease related burdens was £7.06 billion, the highest of all diseases in the UK for which comparable analyses have been done.

Conclusions: Coronary heart disease is a leading public health problem in the UK in terms of the economic burden from disease. Cost estimates would be substantially understated if informal care/productivity costs were excluded.

Keywords: coronary heart disease; cost analysis; health care costs

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Lindsay, S., Smith, S., Bellaby, P., Baker, R. (2009). The health impact of an online heart disease support group: a comparison of moderated versus unmoderated support. Health Educ Res 24: 646-654 [Abstract] [Full Text]  
• Body, R, Carley, S, McDowell, G, Ferguson, J, Mackway-Jones, K (2009). Can a modified thrombolysis in myocardial infarction risk score outperform the original for risk stratifying emergency department patients with chest pain?. Emerg. Med. J. 26: 95-99 [Abstract] [Full Text]  
• Saka, O., McGuire, A., Wolfe, C. (2009). Cost of stroke in the United Kingdom. Age Ageing 38: 27-32 [Abstract] [Full Text]  
• Hamm, C. W., Möllmann, H., Bassand, J.-P., van de Werf, F. (2009). CHAPTER 16 Acute Coronary Syndromes. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Lindsay, S., Bellaby, P., Smith, S., Baker, R. (2008). Enabling healthy choices: is ICT the highway to health improvement?. Health (London) 12: 313-331 [Abstract]  
• Hernandez, R., Vale, L. (2007). The Value of Myocardial Perfusion Scintigraphy in the Diagnosis and Management of Angina and Myocardial Infarction: A Probabilistic Economic Analysis. Med Decis Making 27: 772-788 [Abstract]  
• Fidan, D., Unal, B., Critchley, J., Capewell, S. (2007). Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010. QJM 100: 277-289 [Abstract] [Full Text]  
• Jaumdally, R., Varma, C., Macfadyen, R. J., Lip, G. Y.H. (2007). Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment?. Eur Heart J 28: 929-940 [Abstract] [Full Text]  
• Luengo-Fernandez, R, Leal, J, Gray, A, Petersen, S, Rayner, M (2006). Cost of cardiovascular diseases in the United Kingdom. Heart 92: 1384-1389 [Abstract] [Full Text]  
• Leal, J., Luengo-Fernandez, R., Gray, A., Petersen, S., Rayner, M. (2006). Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 27: 1610-1619 [Abstract] [Full Text]  
• Walker, A, McMurray, J, Stewart, S, Berger, W, McMahon, A D, Dargie, H, Fox, K, Hillis, S, Henderson, N J K, Ford, I (2006). Economic evaluation of the impact of nicorandil in angina (IONA) trial.. Heart 92: 619-624 [Abstract] [Full Text]  
• Bennett, K., Kabir, Z., Unal, B., Shelley, E., Critchley, J., Perry, I., Feely, J., Capewell, S. (2006). Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000.. J. Epidemiol. Community Health 60: 322-327 [Abstract] [Full Text]  
• Saxena, S., George, J., Barber, J., Fitzpatrick, J., Majeed, A. (2006). Association of population and practice factors with potentially avoidable admission rates for chronic diseases in London: cross sectional analysis. JRSM 99: 81-89 [Abstract] [Full Text]  
• Unal, B., Critchley, J. A., Capewell, S. (2004). Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000. Circulation 109: 1101-1107 [Abstract] [Full Text]